Local tumor heating plus immune stimulants to boost checkpoint therapy for metastatic pancreatic cancer
Official title: Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
Funded at University of Oklahoma · NIH-11294281 · Data updated 2026-11-12
This approach uses a targeted tumor-heating treatment together with immune-stimulating drugs to help people with advanced pancreatic cancer get a stronger response to immune checkpoint therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $489,473 |
| NIH project number | 5R01CA269897-05 |
| Project ID | NIH-11294281 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with unresectable or metastatic pancreatic cancer who are eligible for immune checkpoint therapy and can tolerate a local ablation procedure and clinic visits would be the ideal candidates.
✕Less likely to help
People with early-stage resectable pancreatic cancer, those who cannot undergo local ablation or immunotherapy, or tumors not reachable for localized treatment are less likely to benefit.
What this research studies
If I join, doctors will heat and destroy part of my pancreatic tumor with a focused photothermal treatment, then inject immune-stimulating medicine directly into the treated area while giving standard immune checkpoint drugs systemically. The local heating is meant to release tumor antigens and, together with the injected stimulants, turn the tumor into a kind of vaccine that attracts and activates T cells. The team will follow tumor size at treated and distant sites, measure immune activity, and track side effects to see how my body responds. This builds on lab work and early human experience but needs larger clinical testing to confirm benefits and safety.
Why it matters
Potential benefit: If successful, this could make immunotherapy work better for people with metastatic pancreatic cancer by generating stronger, body-wide anti-tumor immune responses.
How similar studies have gone: Preclinical studies and small early clinical experiences combining local photothermal ablation with immune stimulants have shown elimination of treated tumors and some control of distant metastases, but larger human trials remain limited.
Where this research is happening
-
University of Oklahoma
Norman, United States Active
Researchers
- Principal investigator: Chen, Wei R. — University of Oklahoma
- Study coordinator: Chen, Wei R.
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.